Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cortex (Cor) [formerly CORX] -- Ignore unavailable to you. Want to Upgrade?

To: John Lacelle who wrote (677)	11/8/1998 2:59:00 PM
From: DavidCG	Respond to of 1255

No, we all don't know that. Prior to this quarterly report released after the bell on Friday, there is no mention of a Mid-sized European Pharmaceutical company. This is a new development. Period. CORX, like all biotechs, do not analyze data or release data until each study is done. So it is very simple. Since we can not be told about how well clinical trials are going. We must use other external factors to see how well CORX might be doing. You are incorrectly using CORX stock price to judge its success in clinical trials. Price decline of a stock can happen for a myriad of external reasons. (If you need proof of this... look to the stock market from 9300 to 7500 and back to 9000) I prefer to use a Pharmaceutical partnership as the most reliable indicator for CORX's future. You should also focus there as well. It is an extremely simple concept to grasp. If CORX signs an partnership agreement...and the more CORX reveals about the discussions, the more confidence I have an agreement will be signed soon....it would demonstrate confidence from an INDEPENDENT, OUTSIDE party that CORX has a marketable drug for alzheimers/scitzophrenia. After all, there are plenty of sub $1 bio-techs out there in the world. Most of them have no financing because they can not convince a larger pharmaceutical that they have an effective drug for treatment. So surely, you have to admit, if an agreement is signed. It can only mean one thing: CORX has an effective drug. Because the larger pharmaceutical company would be putting its millions of dollars where its mouth is. So, I suggest we all clam up and see what takes place between now and December 1998. Let the actions of this European Pharmaceutical firm do the talking. What this European pharmaceutical company ultimately decides to do will outline CORX's future. To that, we can all agree. -DavidCG